Education
About Us
Working with TipRanks
Follow Us
Orasure Technologies (DE:EP3)
FRANKFURT:EP3
Earnings Data
Report Date
May 13, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.18Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlights clear progress on strategic priorities: revenue slightly beat guidance midpoint, meaningful improvement in gross margins year-over-year, strong cash position with no debt, two significant FDA submissions targeting midyear launches, tangible international expansion (Canada launch, nearshoring in Africa) and early success integrating BiMedomics. Offsetting these positives are sizable operating losses and negative operating cash flow, a multi-year timeline to return to operating cash flow breakeven (target 2027), lingering funding-related headwinds in international public-health markets, regulatory timing uncertainty for new product launches, and under-utilized capacity that makes margin improvement contingent on revenue ramp. Overall, the call conveys cautious optimism grounded in a solid balance sheet and promising near-term product catalysts but tempered by execution risk and the need for top-line recovery to fully realize margin and cash-flow benefits.Company Guidance
Q4 Revenue Beat and Core Revenue
Total revenue of $26.8 million in Q4 2025; core revenue (ex-COVID) $26.7 million, above the midpoint of guidance.
Segment Revenue Detail
Diagnostic Products revenue of $15.1 million and Sample Management Solutions revenue of $9.1 million in Q4, both consistent with expectations.
Improved Gross Margins Year-over-Year
GAAP gross margin improved to 41.0% in Q4 2025 from 36.2% in Q4 2024 (increase of 4.8 percentage points). Non-GAAP gross margin was 41.4% versus 40.1% in Q4 2024 (increase of 1.3 percentage points).
Strong Balance Sheet and Capital Return
Ended year with $199 million in cash and cash equivalents and zero debt. Share repurchases totaled $5 million in Q4 (1.9 million shares) and $15 million year-to-date (5.3 million shares) in 2025.
Two Major FDA Submissions and Near-Term Product Catalysts
Submitted two separate FDA applications in December: a rapid molecular OTC self-test for chlamydia/gonorrhea (Sherlock CT/NG) and the Colli-Pee at-home urine collection device for STIs. Management is targeting midyear launches with revenue ramp expected in H2 2026. Company estimates CT/NG TAM > $1.5 billion.
International Expansion and New Market Entry
Expanded presence in Canada with launch of OraQuick HIV Self-Test (first oral HIV self-test licensed in Canada) via exclusive distributor. Order trends in international diagnostics are stabilizing and nearshoring initiatives in Africa (in-country assembly/manufacturing) expected to contribute revenue starting in Q1 2026.
Acquisition Integration Progress
BiMedomics acquisition (≈$4 million investment in Q4) integration off to a good start, with strong demand for Sickle SCAN Sickle test and plans to leverage existing international channels (Africa, Latin America) to expand reach.
Operational Efficiency Moves
Completed major manufacturing consolidations (moving volumes into Bethlehem facility and internalizing ~95–97% of prior outsourced sample management volume), positioning the company to benefit from overhead absorption as volumes increase and expecting modest sequential gross margin improvement in Q1 2026 (low 40% range).
DE:EP3 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:EP3 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 25, 2026 | €2.36 | €2.58 | +9.32% |
Nov 05, 2025 | €2.22 | €2.04 | -8.11% |
Aug 05, 2025 | €2.68 | €2.56 | -4.48% |
May 07, 2025 | €2.46 | €2.38 | -3.25% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Orasure Technologies (DE:EP3) report earnings?
Orasure Technologies (DE:EP3) is schdueled to report earning on May 13, 2026, After Close (Confirmed).
What is Orasure Technologies (DE:EP3) earnings time?
Orasure Technologies (DE:EP3) earnings time is at May 13, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Orasure Technologies stock?
The P/E ratio of Orasure Technologies is N/A.
What is DE:EP3 EPS forecast?
DE:EP3 EPS forecast for the fiscal quarter 2026 (Q1) is -0.17.